In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)
Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy
CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.
Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
The Canadian Cancer Trials Group offices at Queen's University remain open however, due to the evolving COVID-19 situation, CCTG staff are now working remotely with a limited support team on-site. The most up-to-date information on the status of the Group is available on this page. If you are a trial patient or family member who has a COVID-19 related question please email us at: info_covid19_public@ctg.queensu.ca
While these times are challenging, we appreciate your patience and input as we all continue to support our centers, hospitals, patients and families.
CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
If you are an adult diagnosed with cancer within the last 10 years find out how you can participate.
As the health care systems in Canada ramp up to meet the coming COVID-19 (Coronavirus) challenges, the Canadian Cancer Trials Group (CCTG) recognizes that this may have an impact on the conduct and availability of cancer clinical trials.
People living with cancer are at an increased risk from COVID-19 because of underlying medical conditions and a compromised immune system. Patient care, safety and well-being are a priority while we work to minimize the impact and duration of this pandemic.
Challenges for patients participating in a trial may arise from; social distancing requirements, cancer centre restrictions, travel limitations, interruptions to the supply of investigational products, or because of the strain on hospital resources. These challenges may lead to difficulties in meeting trial-specified procedures, including following trial-mandated visits or follow-up, and access to laboratory or diagnostic testing.
As the COVID-19 situation continues to evolve, CCTG is closely monitoring the situation in consultation with our network of investigators and trial staff. The CCTG Operations and Statistical Centre remains operational and has full capabilities to support trial develop and oversight of the current portfolio.For the safety of our community we have completed a transition to remote work for our staff.
As a faculty that is involved in healthcare, our primary focus in any outbreak is the health and safety of the populations that we serve, and maintaining the working capacity of the healthcare institutions and organizations where we work. Given the rapidly-changing epidemiology of COVID-19, we are using this page to keep Faculty of Health Sciences faculty, staff and students up to date on our protocol.
Keep up to date here.
Queen’s University administrators are actively monitoring reports on the evolving outbreak of coronavirus COVID-19 that can cause acute upper respiratory illness and pneumonia. Protecting the health and safety of our students, staff, and faculty, whether on campus in Kingston, at SmithToronto, the Bader International Study Centre (BISC), or elsewhere in the world, are our primary concerns, and we are continuously assessing what may be required in response to any spread of the virus.
CCTG has continued to monitor the developments pertaining to the coronavirus (COVID-19). After careful consideration and evaluation of available information at this time, and out of an abundance of caution for the entire network, the CCTG Annual Spring Meeting for 2020 is cancelled.
CCTG Network Members,
CCTG is actively monitoring the continuing developments pertaining to the coronavirus (COVID-19) . This includes reviewing reliable sources of information nationally and internationally as well as tracking travel restrictions. We are evaluating risks to patient safety, trial conduct and integrity, as well as critical meetings and engagement activities across the network. Safety and security are our top priorities as we review the situation.
